Aikido Pharma Inc Stock News

AIkido Pharma Inc. (NASDAQ:AIKI) has a beta value of 1.43 and has seen 2.34 million shares traded in the last trading session. The company, currently valued at $56.09M, closed the last trade at $0.65 per share which meant it lost $0.0 on the day or -0.92% during that session. The AIKI stock price is -292.31% AIkido Pharma Inc. (AIKI) Drops -0.92%, Marking Lose By Bears Read More »

AIkido Pharma Inc. (NASDAQ:AIKI) with the stream of -0.92% also noticed, India Golden Minerals Company (AMEX:AUMN) encountered a rapid change of 7.01% in the last hour of Tuesdays trading session. The post Stock Alert: AIkido Pharma Inc. (NASDAQ:AIKI), Golden Minerals Company (AMEX:AUMN) appeared first on Stocks Equity .

Zacks Investment Research downgraded shares of AIkido Pharma (NASDAQ:AIKI) from a buy rating to a hold rating in a research report report published on Thursday, Zacks.com reports. According to Zacks, AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The companys pipeline of therapeutics includes therapies [] The post AIkido Pharma (NASDAQ:AIKI) Cut to Hold at Zacks Investment Research appeared first on ETF Daily News .

AIkido Pharma Inc. (NASDAQ:AIKI) with the stream of 3.71% also noticed, India Sibanye Stillwater Limited (NYSE:SBSW) encountered a rapid change of -1.30% in the last hour of Fridays trading session. The post Traders should divert their intention on this Stock: AIkido Pharma Inc. (NASDAQ:AIKI), Sibanye Stillwater Limited (NYSE:SBSW) appeared first on Stocks Equity .

AIkido Pharma Inc. (NASDAQ:AIKI) shares, rose in value on Friday, 12/17/21, with the stock price up by 3.71% to the previous days close as strong demand from buyers drove the stock to $0.68. Actively observing the price movement in the last trading, the stock closed the session at $0.66, falling within a range of $0.642 AIkido Pharma Inc. (NASDAQ: AIKI) To Drop -194.12% In Near Future Read More »

Zacks Investment Research cut shares of AIkido Pharma (NASDAQ:AIKI) from a buy rating to a hold rating in a report released on Thursday morning, Zacks.com reports. According to Zacks, AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics. The companys pipeline of therapeutics includes therapies for []

AIkido Pharma Inc. (NASDAQ:AIKI) with the stream of 1.66% also noticed, India Hycroft Mining Holding Corporation (NASDAQ:HYMC) encountered a rapid change of -0.28% in the last hour of Wednesdays trading The post Oscillating Stock: AIkido Pharma Inc. (NASDAQ:AIKI), Hycroft Mining Holding Corporation (NASDAQ:HYMC) appeared first on Stocks Equity .

Zacks Investment Research upgraded shares of AIkido Pharma (NASDAQ:AIKI) from a hold rating to a buy rating in a research report released on Monday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 price target on the business services providers stock. According to Zacks, AIkido Pharma Inc. is a biotechnology development company with a diverse []

Analysts expect that AIkido Pharma Inc. (NASDAQ:AIKI) will post earnings per share of ($0.01) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for AIkido Pharmas earnings. AIkido Pharma posted earnings of $0.05 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 120%. The []

AIkido Pharma (NASDAQ:AIKI) and Absci (NASDAQ:ABSI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends. Analyst Ratings This is a summary of current ratings and target prices for AIkido Pharma and []

NEW YORK, Dec. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes. ASP Isotopes'' Aerodynamic

AIkido Pharma (NASDAQ: AIKI) is one of 42 publicly-traded companies in the Commercial physical research industry, but how does it compare to its rivals? We will compare AIkido Pharma to similar companies based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, risk and dividends. Valuation and Earnings This table compares AIkido []

AIkido Pharma Inc. (AIKI) with the stream of -3.87% also noticed, India Phillips 66 (PSX) encountered a rapid change of -1.93% in the last hour of trading session. AIkido Pharma The post Traders cant Passover this Stock: AIkido Pharma Inc. (NASDAQ:AIKI), Phillips 66 (NYSE:PSX) appeared first on Stocks Equity .

AIkido Pharma (NASDAQ:AIKI) and Science 37 (NASDAQ:SNCE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation. Institutional and Insider Ownership 10.3% of AIkido Pharma shares are owned by institutional investors. 0.6% []

AIkido Pharma (NASDAQ: AIKI) is one of 42 public companies in the Commercial physical research industry, but how does it compare to its rivals? We will compare AIkido Pharma to related companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, profitability, dividends and risk. Volatility & Risk AIkido Pharma has a []